All In MedTech

Device Trial Radar · NCT03487887

Secondary Care - Continuous Glucose Monitoring

Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Secondary Care

Last checked: Nov 19, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Mar 19, 2018

Primary completion

Aug 25, 2021

Study completion Aug 25, 2021

Sponsor

Lead sponsor
Croatian Society for Endocrinology and DiabologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takeda
First posted
Apr 4, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 3 days, up to 8 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got the potential to revolutionize diabetes care in the near future striving to optimal diabetes management and tight glucose control. Until very recently, this determination could only be achieved by the attainment of multiple capillary blood glucose determinations each day and/or measuring hemoglobin A1C. Those methods are not accurate in cases of unrecognized hypoglycemia, unrecognized nighttime events or in cases of large swings in blood glucose. Our aim is to analyze the benefit of tracking patterns of glucose values by using professional CGM technology used for "blinded" collection of glucose data retrospectively in patients with T2DM in secondary care- diabetologist clinic.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • continuous glucose monitoring (CGM) iPro™2 MedtronicDevice

    A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glycemic variabilityTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Centre Zagreb

    Zagreb, Croatia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.